Correspondence (letter to the editor): National foundation
- PMID: 20953259
- PMCID: PMC2954522
- DOI: 10.3238/arztebl.2010.0671a
Correspondence (letter to the editor): National foundation
Comment on
-
The financing of drug trials by pharmaceutical companies and its consequences. Part 1: a qualitative, systematic review of the literature on possible influences on the findings, protocols, and quality of drug trials.Dtsch Arztebl Int. 2010 Apr;107(16):279-85. doi: 10.3238/arztebl.2010.0279. Epub 2010 Apr 23. Dtsch Arztebl Int. 2010. PMID: 20467553 Free PMC article.
-
The financing of drug trials by pharmaceutical companies and its consequences: part 2: a qualitative, systematic review of the literature on possible influences on authorship, access to trial data, and trial registration and publication.Dtsch Arztebl Int. 2010 Apr;107(17):295-301. doi: 10.3238/arztebl.2010.0295. Epub 2010 Apr 30. Dtsch Arztebl Int. 2010. PMID: 20490338 Free PMC article.
Similar articles
-
Correspondence (letter to the editor): Search bias.Dtsch Arztebl Int. 2010 Sep;107(38):671-2; author reply 673-4. doi: 10.3238/arztebl.2010.0671b. Epub 2010 Sep 24. Dtsch Arztebl Int. 2010. PMID: 20953260 Free PMC article. No abstract available.
-
Correspondence (letter to the editor): Notorious weaknesses.Dtsch Arztebl Int. 2010 Sep;107(38):670; author reply 673-4. doi: 10.3238/arztebl.2010.0670a. Epub 2010 Sep 24. Dtsch Arztebl Int. 2010. PMID: 20953258 Free PMC article. No abstract available.
-
FDA publishes conflict of interest rules for clinical trials. Food and Drug Administration.AIDS Treat News. 1998 Mar 6;(No 290):8. AIDS Treat News. 1998. PMID: 11365123
-
[Consequences of the German anticorruption law for sponsorship at university hospitals].Wien Med Wochenschr. 2002;152(9-10):246-8. doi: 10.1046/j.1563-258x.2002.02038.x. Wien Med Wochenschr. 2002. PMID: 12094401 German.
-
Managing conflicts of interest: a survival guide for biotechs.Nat Biotechnol. 2007 Feb;25(2):161-3. doi: 10.1038/bioent915. Nat Biotechnol. 2007. PMID: 17375384 Review.
References
-
- Schott G, Pachl H, Limbach U, Gundert-Remy U, Ludwig WD, Lieb K. The financing of drug trials by pharmaceutical companies and its consequences: Part 1. A qualitative, systematic review of the literature on possible influences on the findings, protocols, and quality of drug trials. Dtsch Arztebl Int. 2010;107(16):279–285. - PMC - PubMed
-
- Schott G, Pachl H, Limbach U, Gundert-Remy U, Ludwig WD, Lieb K. The financing of drug trials by pharmaceutical companies and its consequences: Part 2. A qualitative, systematic review of the literature on possible influences on authorship, access to trial data, and trial registration and publication. Dtsch Arztebl Int. 2010;107(17):295–301. - PMC - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical